fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Levodopa & benserazide

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Prolopa 50-12.5 · DIN 00522597 · 50 mg & 12.5 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Prolopa 50-12.5 · DIN 00522597 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1981-12-31 · brand PROLOPA CAP 50-12.5 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 12.5 MG, LEVODOPA 50 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Prolopa 50-12.5: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3508). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00522597)

Source record
DIN 00522597: Prolopa 50-12.5 Raw flags: sec3=Y Item: 920000037; group id 930; item number 2216; lccId None; manufacturer id HLR Source form: Cap; strength: 50mg & 12.5mg Recorded listing: General benefit Source prices (unrounded): $0.3508; ministry $0.3508 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00522597 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4459
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522597
Shortage record checked October 6, 2026

Prolopa 100-25 · DIN 00386464 · 100 mg & 25 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Prolopa 100-25 · DIN 00386464 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1977-12-31 · brand PROLOPA CAP 100-25 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients LEVODOPA 100 MG, BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 25 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Prolopa 100-25: Formulary list price $0.58 per unit (the source does not state the unit; exact figure $0.5777). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00386464)

Source record
DIN 00386464: Prolopa 100-25 Raw flags: sec3=Y Item: 920000027; group id 930; item number 2217; lccId None; manufacturer id HLR Source form: Cap; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.5777; ministry $0.5777 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00386464 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2723
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00386464
Shortage record checked October 6, 2026

Prolopa 200-50 · DIN 00386472 · 200 mg & 50 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Prolopa 200-50 · DIN 00386472 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 1977-12-31 · brand PROLOPA CAP 200-50 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Capsule · route Oral · ingredients LEVODOPA 200 MG, BENSERAZIDE (BENSERAZIDE HYDROCHLORIDE) 50 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Prolopa 200-50: Formulary list price $0.97 per unit (the source does not state the unit; exact figure $0.9699). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00386472)

Source record
DIN 00386472: Prolopa 200-50 Raw flags: sec3=Y Item: 920000026; group id 930; item number 2218; lccId None; manufacturer id HLR Source form: Cap; strength: 200mg & 50mg Recorded listing: General benefit Source prices (unrounded): $0.9699; ministry $0.9699 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00386472 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2724
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00386472
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N04B, N04BA): coverage varies; not interchangeable

  • Carbidopa + levodopa (Sinemet CR): general benefit, limited Use, not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367
  • Amantadine (Symmetrel): general benefit, not a benefit
  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Ropinirole (ReQuip): general benefit, not a benefit
  • Selegiline (Eldepryl): general benefit, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults > 25 years of age PROLOPA (levodopa and benserazide capsules) is indicated for the treatment of Parkinson’s disease with the exception of drug-induced parkinsonism. The administration of PROLOPA is associated with amelioration of the symptoms of Parkinson’s disease with the advantage that combined therapy significantly diminishes the incidence of the levodopa-induced peripheral side-effects of nausea, vomiting and possibly cardiac arrhythmias. This results in an advantage for those patients who previously were unable to tolerate an optimal daily dosage of levodopa. Improved gastrointestinal tolerance also provides for a more rapid induction of therapy, e.g., optimum dosage can in most cases be achieved within two to three weeks. However, combined therapy with levodopa and benserazide increases the incidence of centrally mediated abnormal movements earlier in therapy and can lead to an earlier appearance of oscillations in performance. Thus, when combined therapy with levodopa and benserazide is instituted it is important to strive at using and maintaining a dosage regimen which balances efficacy with freedom from dyskinesias. Despite the dra… https://pdf.hres.ca/dpd_pm/00052550.PDF PM date: August 2, 2019 Source product: PROLOPA CAP 100-25; DIN 00386464; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18